A federal appeals court held that Novartis’ patent on the blockbuster multiple sclerosis drug Gilenya was invalid, according to a Reuters article.
The U.S. Circuit Court of Appeals for the Federal Circuit affirmed a 2015 ruling by the U.S. Patent Trial and Appeal Board, which agreed with generic drug manufacturers Torrent Pharmaceuticals, Apotex and Mylan Pharmaceuticals that the Gilenya patent was obvious, the story said.
Read the full story